### UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE VALSARTAN, LOSARTAN, AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

THIS DOCUMENT RELATES TO ALL CASES

**MDL No. 2875** 

HON. ROBERT B. KUGLER CIVIL NO. 19-2875 (RBK)

**Redacted Version** 

# PLAINTIFFS' DAUBERT MOTION AND INCORPORATED MEMORANDUM OF LAW TO PRECLUDE OPINIONS OF DEFENSE EXPERT TIMOTHY ANDERSON, M.S., M.B.A.

KANNER & WHITELEY, LLC 701 Camp St.
New Orleans, LA 70130

On the Brief: David J. Stanoch, Esq.

#### **TABLE OF CONTENTS**

TAB	BLE OF AUTHORITIES	ii
I.	INTRODUCTION	1
II.	LEGAL STANDARD	3
A.	Rule 26 and the Contents of the Expert Report	3
B.	Daubert Standard	4
III.	ARGUMENT	6
A. 1 2	1.	Be Precluded
В.	Mr. Anderson's Various Opinions About	Should Be Precluded13
C.	Mr. Anderson Is Not	17
IV.	CONCLUSION	19

PageID: 81194

Contains Confidential Information Subject to Protective Order

#### TABLE OF AUTHORITIES

Page(s) **Cases** ABB Air Preheater, Inc. v. Regenerative Env't Equip. Co., 167 F.R.D. 668 (D.N.J. 1996) ......4 Apotex, Inc. v. Cephalon, Inc., Brooke Grp. Ltd. v. Brown & Williamson Tobacco Corp., Claar v. Burlington, N.R.R. 29 F.3d 499 (9th Cir. 1994)......5 Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311 (9th Cir. 1995)......5 Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) ......4 Elcock v. Kmart Corp., 233 F.3d 734 (3d Cir. 2000)......5 General Elec. Co. v. Joiner. 522 U.S. 136 (1997) ......5 GlaxoSmithKline, *In re Paoli R.R. Yard PCB Litigation*, Kumho Tire Co. v. Carmichael, Lipton v. Mountain Creek Resort, Inc., No. CV134866KMMAH, 2019 WL 4597205 (D.N.J. Sept. 23, 2019) ......4 Magistrini v. One Hour Martinizing Dry Cleaning, 180 F. Supp. 2d 584 (D.N.J. 2002)......5

### 

Contains Confidential Information Subject to Protective Order

## **Regulations**21 C.F.R. § 210.1 ......8

Filed 03/13/23

Page 6 of 25

Contains Confidential Information Subject to Protective Order

#### I. <u>INTRODUCTION</u>

Plaintiffs submit this Daubert motion against Teva's expert, Timothy
Anderson, with regard to his opinions that
First, like Teva's other expert Dr. Roger Williams, Mr. Anderson opines that
From this faulty premise, Mr. Anderson extrapolates that,
Mr. Anderson's are fatally flawed. For one, the FDA
expressly stated that ZHP's valsartan API was adulterated. Therefore, Teva's VCDs
incorporating that same adulterated API were adulterated as well.
More fundamentally, an adulterated product is one not made in a cGMP-
compliant manner, or that lacks appropriate purity, quality, identity, and other
characteristics. Teva's VCDs fell into each of these buckets for years prior to the
July 2018 recalls. Mr. Anderson lacks any basis for
. Were his peculiar view correct

Document 2297-1 PageID: 81198


Filed 03/13/23 Page 7 of 25

then a firm could
. This is akin to saying a state-law tort
claim cannot lie against a firm that negligently sold poisoned milk because the
plaintiff already bought and drank the milk before the poison was discovered by the
FDA (or anyone else). Mr. Anderson's flow from an
unreliable methodology untethered to law or fact, rendering them unhelpful.
Second, Mr. Anderson proffers a bevy of opinions about
This includes Teva's
There is just one problem: Mr. Anderson exclusively looks at
. But Mr. Anderson admits

Document 2297-1 PageID: 81199 Filed 03/13/23

Page 8 of 25

Contains Confidential Information Subject to Protective Order



Third, Mr. Anderson repeatedly

But he lacks any qualifications to go before the jury as such an expert. His

is not a specialized skill beyond the ken of an average juror.

For these reasons, expressed more fully below, Mr. Anderson's opinions identified herein should be precluded.

#### II. <u>LEGAL STANDARD</u>

#### A. Rule 26 and the Contents of the Expert Report

Federal Rule of Civil Procedure 26(a)(2) governs the disclosure of expert testimony and specifically the contents of an expert report. Relevant to this Motion, the Rule states the following: "The report must contain: (i) a complete statement of all opinions the witness will express and the basis and reasons for them; (ii) the facts or data considered by the witness in forming them ...." Fed. R. Civ. P. 26(a)(2)(B)(i) & (ii). A failure to submit an expert report that complies with Rule 26 is an independent basis for the exclusion of the expert's testimony. See, e.g., Meyers v. Nat'l R.R. Pass. Corp. (Amtrak), 619 F.3d 729, 734 (7th Cir. 2010) ("The

PageID: 81200

Contains Confidential Information Subject to Protective Order

consequence of non-compliance with Rule 26(a)(2)(B) is exclusion of an expert's testimony[.]" (internal quotations and citations omitted)).

Experts are therefore only permitted to testify at trial in accordance with the contents of their reports. *See* Fed. R. Civ. P. 26(a)(2)(B)(i); *see also Lipton v. Mountain Creek Resort, Inc.*, No. CV134866KMMAH, 2019 WL 4597205, at \*7 (D.N.J. Sept. 23, 2019) ("[T]he court generally will not permit an expert to testify beyond the scope of his or her report."). "Compliance with Rule 26(a)(2) is thus a condition precedent to the use of expert testimony at trial." *ABB Air Preheater, Inc. v. Regenerative Env't Equip. Co.*, 167 F.R.D. 668, 671 (D.N.J. 1996).

#### B. Daubert Standard

The admissibility of expert testimony is determined pursuant to Federal Rule of Evidence 702. The party offering the proposed expert testimony bears the burden of establishing the admissibility of the testimony by a preponderance of the evidence. *Padillas v. Stork-Gamco, Inc.*, 186 F.3d 412, 417-18 (3d Cir. 1999). An "expert's opinions must be based on the methods and procedures of science, rather than on subjective belief or unsupported speculation." *In re Paoli R.R. Yard PCB Litigation*, 35 F.3d 717, 742 (3d Cir. 1994) (citations and internal quotations omitted).

Thus, "the expert must have 'good grounds' for his or her belief." *Id.* (quoting *Daubert v. Merrell Dow Pharmaceuticals, Inc.*, 509 U.S. 579,

Contains Confidential Information Subject to Protective Order

590 (1993)). These good grounds must support each step of the analysis and, "any step that renders the analysis unreliable under the *Daubert* factors renders the expert's testimony inadmissible." *Id.* at 745. Judges within this Circuit also consider how and when the methodology is used outside of litigation. *Paoli*, 35 F.3d at 742 (discussing reliability factors under *Daubert* and Third Circuit case law).

Furthermore, "Daubert's gatekeeping requirement .... make[s] certain that an expert, whether basing testimony upon professional studies or personal experience, employs in the courtroom the same level of intellectual rigor that characterizes the practice of an expert in the relevant field." Elcock v. Kmart Corp., 233 F.3d 734, 746 (3d Cir. 2000) (quoting Kumho Tire Co. v. Carmichael, 526 U.S. 137, 152 (1999)); see also Magistrini v. One Hour Martinizing Dry Cleaning, 180 F. Supp. 2d 584, 594 (D.N.J. 2002), aff'd, 68 Fed. App'x 356 (3d Cir. 2003). In addition, the following factors are relevant when determining reliability:

(i) whether the expert's proposed testimony grows naturally and directly out of research the expert has conducted independent of the litigation (*see Daubert v. Merrell Dow Pharmaceuticals, Inc.*, 43 F.3d 1311, 1317 (9th Cir. 1995)); (ii) whether the expert has unjustifiably extrapolated from an accepted premise to an unfounded conclusion (*see General Elec. Co. v. Joiner*, 522 U.S. 136, 146, 118 S. Ct. 512, 139 L.Ed.2d 508 (1997)); (iii) whether the expert has adequately accounted for alternative explanations (*see Claar v. Burlington, N.R.R.*, 29 F.3d 499 (9th Cir. 1994)).

Magistrini, 180 F. Supp. 2d at 594–95.

Filed 03/13/23 Page 11 of 25

Contains Confidential Information Subject to Protective Order

#### III. ARGUMENT

#### A. Mr. Anderson's

Should Be Precluded<sup>1</sup>

A product is adulterated

if it is a drug and the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.

21 U.S.C. § 351(a)(2)(B).<sup>2</sup> Contamination renders a drug adulterated, as does failure to comply with any cGMP regulation concerning the manufacture, processing, packing or holding of a drug (even in the absence of contamination). *See id.*; *see also* 21 C.F.R. § 210.1(b). Both past and future cGMP violations may result in adulteration. *See, e.g., United States v. Barr Labs., Inc.*, 812 F. Supp. 458, 487 (D.N.J. 1993) (discussing both past and future cGMP violations resulting in adulteration).


Expert testimony that is contrary to law or fact, or that seeks to misstate the applicable law to the jury, is unhelpful. See, e.g., SEC v. Ambassador Advisors,

-

Because Teva's experts, Dr. Williams and Mr. Anderson, share the same flawed, this section largely appears verbatim in this Motion as well as the contemporaneously filed motion to preclude Dr. Williams' opinions.

<sup>&</sup>lt;sup>2</sup> For ease, this Motion refers to federal law, but of course Plaintiffs' claims arise under parallel, non-preempted state laws that impose identical state requirements.

LLC, 576 F. Supp. 3d 250 (E.D. Pa. Dec. 21, 2021). An expert's opinion is inadmissible if it "is both contrary to the record . . . [and] is contrary to the law." See, e.g., Apotex, Inc. v. Cephalon, Inc., 321 F.R.D. 220, 236 (E.D. Pa. 2017). Mr. Anderson's adulteration opinions should be precluded they unreliably run contrary to law and fact, as discussed more fully below.



 $<sup>^3</sup>$  Mr. Anderson submitted a declaration and gave testimony at the class certification stage that included the  $^{\circ}$  . He confirmed his prior testimony during his liability-stage deposition last month. See Ex. 2 (Anderson 2/9/23 Tr.) at 12:16-13:2.

on

Contains Confidential Information Subject to Protective Order

. See, e.g., United States v. 789 Cases, More or Less, of Latex Surgeons' Gloves, an Article of Device, 799 F. Supp. 1275, 1296 (D.P.R. 1992).

Document 2297-1

PageID: 81204

Adulteration does not turn on whether the FDA, with its limited resources, catches a firm violating cGMPs and issues a formal statement about it. Rather, each firm engaged in the manufacture and distribution of drugs has self-executing obligations to ensure its products and practices comply with cGMPs at all times. As the FDA puts it: "If a company is not complying with CGMP regulations, any drug it makes is considered 'adulterated' under the law. This kind of adulteration means that the drug was not manufactured under conditions that comply with CGMP."<sup>4</sup>

Despite being contrary to law, fact, and common sense, Mr. Anderson's

. Here,	
	See Ex. 4.
	See E.N. II

F--4- A1---41-- C-----

<sup>&</sup>lt;sup>4</sup> Facts About the Current Good Manufacturing Practices (CGMPSs), *at* <a href="https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps">https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps</a> (last visited Feb. 17, 2023); *see also* 21 C.F.R. §§ 210.1, 211.1.



That same ZHP valsartan API had been incorporated into each and every one of Teva's VCDs at issue at this stage of the case. Teva's own corporate designees confirmed, one after the other,

. Ex. 3 (Anderson 3/9/22 Tr.) at 141:8-17.6

<sup>5</sup> See, e.g., Ex. 5 (Lyons Tr.) at 285:3-12 ("

As ZHP's valsartan API was contaminated and made in violation of cGMP, so too, were Teva's VCDs incorporating same. It is baseless, illogical, counterfactual, and certainly unhelpful to the jury for

2.

Mr. Anderson also erroneously contends

<sup>7</sup> Ex. 5 (Lyons Tr.) at 130:3 – 132:2

); see also id. at 275:24 – 276:5.

Subject to Protective Order

Contains Confidential Information

See Ex. 1 at ¶¶ 21, 190.

PageID: 81207

As a threshold matter, the FDA's December 2018 interim limits are immaterial. As Mr. Anderson concedes,

More to the key point, the record and caselaw belies Mr. Anderson's dubious position that

See, e.g., BCBS v. GlaxoSmithKline, No. 13-4663, 2019 WL 4751883, at \*1 (E.D. Pa. Sept. 30, 2019) (seeking economic damages years later for drugs purchased between 2000 to 2005 that were later considered to be adulterated due to cGMP violations); United States v. Titan Med. Enterprises, Inc., No. 2:11-cv-10752, 2013 WL 444034, at \*1 (C.D. Cal. Feb. 4, 2013) (noting, in 2013, that "[f]rom 2001 through 2012, Defendants' drug manufacturing operations

<sup>&</sup>lt;sup>8</sup> Ex. 3 (Anderson 3/9/22 Tr.) at 45:22 – 46:1.

Case 1:19-md-02875-RMB-SAK Document 2297-1 Fil

PageID: 81208

Filed 03/13/23 Page 17 of 25

Contains Confidential Information Subject to Protective Order

did not comply with current good manufacturing practice regulations for drugs...Defendants' drugs are therefore adulterated under 21 U.S.C. § 351(a)(2)(B)."); *Barr*, 812 F. Supp. at 487 ("no dispute" about firm's "past violations" of cGMP).

ZHP's expert, Mr. David Chesney, also confirmed that Ex. 7 (Chesney Tr.) at 189:24-190:3, 195:16-23. Teva's head of quality and Rule 30(b)(6) designee recognized that

Mr. Anderson's strained position further lacks common sense. According to
him,
Unsurprisingly, Mr. Anderson cites no legal
regulatory, or factual support for his astonishing position.
Absent any credible basis in law or fact, Mr. Anderson's
are unreliable, the product of unreliable methods, and unhelpful.
B. Mr. Anderson's Various Opinions About Should B Precluded
See Ex. 1 at ¶¶ 46-47.


Document 2297-1 PageID: 81210 Filed 03/13/23

Page 19 of 25

	During the entire relevant time period, the API for these VCDs were sourced
c I	
from	
	Mr. Anderson proffers a litany of opinions about
	Wit. Anderson proffers a many of opinions about
_	
	<i>Id.</i> ¶ 32.


Filed 03/13/23

Page 20 of 25



Document 2297-1 PageID: 81212 Filed 03/13/23

Page 21 of 25



702(b); United States ex rel. Penelow v. Janssen Prod., LP, No. CV127758ZNQLHG, 2022 WL 94535, at \*3 (D.N.J. Jan. 10, 2022) ("The purported expert's testimony "must be based on the 'methods and procedures of science' rather than on 'subjective belief or unsupported speculation."); Mondis Tech. Ltd. v. LG Elecs., Inc., No. 15-4431, 2021 WL 4077563, at \*3 (D.N.J. Sept. 8, 2021) (experts must have sufficient support in facts or data for conclusions reached); Meadows v. Anchor Longwall & Rebuild, Inc., 306 Fed. App'x 781, 790 (3d Cir. 2009) (opinions resting on "assumptions and conclusions that are not supported by the factual record" should be excluded as they would not "aid the jury in resolving a factual dispute" because they do not "fit under the facts of the case.") (internal citations and quotations omitted). 14

#### C. Mr. Anderson Is Not

At his first deposition, Mr. Anderson repeatedly

See Ex. 3 (3/9/22 Dep.) at 180:8-9


); *id.* at 186:23-24

id. at 322:7-18

<sup>&</sup>lt;sup>14</sup> "When an expert opinion is not supported by sufficient facts to validate it in the eyes of the law, or when indisputable record facts contradict or otherwise render the opinion unreasonable, it cannot support a jury's verdict." *Brooke Grp. Ltd. v. Brown & Williamson Tobacco Corp.*, 509 U.S. 209, 242 (1993) (disregarding unsupported facts put forth by expert at summary judgment stage).

Filed 03/13/23

Page 23 of 25



Document 2297-1 Filed 03/13/23 PageID: 81215

Page 24 of 25

Contains Confidential Information Subject to Protective Order

IV CONCLUSION

#### IV. <u>CONCLUSION</u>

For the foregoing reasons, Mr. Anderson should be precluded from offering

his

Respectfully,

ON BEHALF OF PLAINTIFFS

By: <u>/s/ David J. Stanoch</u>
David J. Stanoch
KANNER & WHITELEY, L.L.C.
701 Camp St.
New Orleans, LA 70130
(504) 524-5777 (t)
(504) 524-5763 (f)
d.stanoch@kanner-law.com

Dated: March 13, 2023

Document 2297-1 PageID: 81216 Filed 03/13/23

Page 25 of 25

Contains Confidential Information Subject to Protective Order

**CERTIFICATE OF SERVICE** 

The undersigned hereby certifies that on March 13, 2023, a true and correct

redacted copy of the foregoing was filed and served via the court's CM/ECF system,

and an unredacted version was served on the court and the Defense Executive

Committee via email.

/s/ David J. Stanoch

David J. Stanoch